Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: A randomised, controlled, double-blind, dose-ranging trial

The Lancet Infectious Diseases

Volumn 14, Issue 2, 2014, Pages 130-139

  Eziefula, Alice C ^a   Bousema, Teun ^a,b   Yeung, Shunmay ^a   Kamya, Moses ^c   Owaraganise, Asiphas ^c   Gabagaya, Grace ^c   Bradley, John ^a   Grignard, Lynn ^a   Lanke, Kjerstin H W ^b   Wanzira, Humphrey ^c   Mpimbaza, Arthur ^c,d   Nsobya, Samuel ^c   White, Nicholas J ^e   Webb, Emily L ^a   Staedke, Sarah G ^a   Drakeley, Chris ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^d MAKERERE UNIVERSITY   (Uganda)

^e MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; PLACEBO; PRIMAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; GAMETOCYTE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; MEDICAL STAFF; PARASITE CLEARANCE; PATIENT CARE; PHOTOMETER; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME; UGANDA; WORLD HEALTH ORGANIZATION; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; INFANT; MALARIA, FALCIPARUM; PARASITE LOAD; RECEIVER OPERATING CHARACTERISTIC;

ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; FOLLOW-UP STUDIES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; PARASITE LOAD; PRIMAQUINE; ROC CURVE; TREATMENT OUTCOME; UGANDA;

EID: 84892519249     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70268-8     Document Type: Article

References (46)

1. Feachem R, Sabot O A new global malaria eradication strategy. Lancet 2008, 371:1633-1635.
2. Meremikwu MM, Donegan S, Sinclair D, Esu E, Oringanje C Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database Syst Rev 2012, 2. CD003756.
3. Sawa P, Shekalaghe SA, Drakeley CJ, et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 2013, 207:1637-1645.
4. Targett G, Drakeley C, Jawara M, et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis 2001, 183:1254-1259.
5. Drakeley CJ, Jawara M, Targett GA, et al. Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes. Trop Med Int Health 2004, 9:53-61.
6. Bousema JT, Schneider P, Gouagna LC, et al. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis 2006, 193:1151-1159.
7. Shekalaghe S, Drakeley C, Gosling R, et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PloS One 2007, 2:e1023.
8. Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010, 10:673-681.
9. Sutanto I, Suprijanto S, Kosasih A, et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in south Sumatra, western Indonesia: an open-label, randomized, controlled trial. Clin Infect Dis 2013, 56:685-693.
10. Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, White NJ Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother 2004, 48:1329-1334.
11. Arango EM, Upegui YA, Carmona-Fonseca J Efficacy of different primaquine-based antimalarial regimens against Plasmodium falciparum gametocytemia. Acta Trop 2012, 122:177-182.
12. Shah NK, Schapira A, Juliano JJ, et al. Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes. Antimicrob Agents Chemother 2013, 57:2948-2954.
13. Mackerras MJ, Ercole QN Observations on the action of quinine, atebrin and plasmoquine on the gametocytes of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1949, 42:455-463.
14. Chen PQ, Li GQ, Guo XB, et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chin Med J 1994, 107:709-711.
15. White NJ Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis 2013, 13:175-181.
16. White NJ, Qiao LG, Qi G, Luzzatto L Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J 2012, 11:418.
17. World Malaria Report 2012 2012, WHO, World Health Organization Global Malaria Programme, Geneva.
18. Shekalaghe SA, Ter Braak R, Daou M, et al. Haemolysis after a single dose of primaquine co-administered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase (G6PD A- variant) deficient individuals in Tanzania. Antimicrob Agents Chemother 2010, 54:1762-1768.
19. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull World Health Organ 1960, 22:621-631.
20. Guidelines for the treatment of malaria 2010, WHO, World Health Organization, Geneva. 2nd edn.
21. Eziefula AC, Staedke SG, Yeung S, et al. Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open 2013, 3:e002759.
22. Okello PE, Van Bortel W, Byaruhanga AM, et al. Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 2006, 75:219-225.
23. Staedke SG, Jagannathan P, Yeka A, et al. Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda. Malar J 2008, 7:107.
24. Schneider P, Schoone G, Schallig H, et al. Quantification of Plasmodium falciparum gametocytes in differential stages of development by quantitative nucleic acid sequence-based amplification. Mol Biochem Parasitol 2004, 137:35-41.
25. Bousema T, Okell L, Shekalaghe S, et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar J 2010, 9:136.
26. Methods for surveillance of antimalarial drug efficacy 2009, WHO, World Health Organization, Geneva.
27. Mendez F, Munoz A, Plowe CV Use of area under the curve to characterize transmission potential after antimalarial treatment. Am J Trop Med Hyg 2006, 75:640-644.
28. Graves PM, Gelband H, Garner P Primaquine for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev 2012, 9. CD008152.
29. Shekalaghe SA, ter Braak R, Daou M, et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother 2010, 54:1762-1768.
30. Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010, 10:673-681.
31. Bousema T, Drakeley C Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 2011, 24:377-410.
32. Ouedraogo AL, Bousema T, Schneider P, et al. Substantial contribution of submicroscopical Plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission. PLoS One 2009, 4:e8410.
33. Schneider P, Bousema JT, Gouagna LC, et al. Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am J Trop Med Hyg 2007, 76:470-474.
34. Churcher TS, Bousema T, Walker M, et al. Predicting mosquito infection from gametocyte density and estimating the reservoir of infection. Elife 2013, 2:e00626.
35. Barnes KI, Little F, Mabuza A, et al. Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. J Infect Dis 2008, 197:1605-1613.
36. Bousema T, Churcher TS, Morlais I, Dinglasan RR Can field-based mosquito feeding assays be used for evaluating transmission-blocking interventions?. Trends Parasitol 2013, 29:53-59.
37. Sutherland CJ, Ord R, Dunyo S, et al. Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med 2005, 2:e92.
38. Hallett RL, Dunyo S, Ord R, et al. Chloroquine/sulphadoxine-pyrimethamine for Gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparum. PLoS Clin Trials 2006, 1:e15.
39. Beutler E, Mitchell M Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. Blood 1968, 32:816-818.
40. Chemotherapy of malaria and resistance to antimalarials. Report of a WHO scientific group. World Health Organization technical report series no. 529 1973, WHO, World Health Organization, Geneva.
41. Baird JK, Surjadjaja C Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol 2011, 27:11-16.
42. Dondorp AM, Fairhurst RM, Slutsker L, et al. The threat of artemisinin-resistant malaria. N Engl J Med 2011, 365:1073-1075.
43. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. Malar J 2012, 11:424. WHO Malaria Policy Advisory Committee and Secretariat.
44. Von Seidlein L Mini primaquine? Controversy and uncertainty surround WHO guidelines for the antimalarial primaquine. Speaking of medicine-PLoS Blog (accessed May 25, 2013). http://blogs.plos.org/speakingofmedicine/2012/10/11/mini-primaquine-controversy-and-uncertainty-surround-who-guidelines-for-the-antimalarial-primaquine/.
45. Stepniewska K, Price RN, Sutherland CJ, et al. Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity. Malar J 2008, 7:249.
46. Howes RE, Piel FB, Patil AP, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med 2012, 9:e1001339.